Inventor · disambiguated record
Christine E. Brown
Also filed as: BROWN CHRISTINE · BROWN CHRISTINE E
18 granted patents·26 pending applications·133 citations·filing 2013–2025
93Inventor score
Top patents by PatentIndex Score
44 records- 0196US9574014B2Chimeric antigen receptor compositionsHOPE CITY·Filed 2016·Granted Feb 21, 2017·41 cites·20 claims
- 0294US11690908B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2021·Granted Jul 4, 2023·3 cites·10 claims
- 0394US11116834B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2017·Granted Sep 14, 2021·10 cites·11 claims
- 0494US9914909B2Costimulatory chimeric antigen receptor T cells targeting IL13Rα2HOPE CITY·Filed 2016·Granted Mar 13, 2018·21 cites·16 claims
- 0593US11197919B2Chimeric antigen receptors targeting HER2HOPE CITY·Filed 2016·Granted Dec 14, 2021·11 cites·60 claims
- 0692US12161714B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2023·Granted Dec 10, 2024·1 cites·6 claims
- 0791US10676717B2Costimulatory chimeric antigen receptor T cells targeting IL13Rα2HOPE CITY·Filed 2018·Granted Jun 9, 2020·5 cites·16 claims
- 0888US9657105B2CD123-specific chimeric antigen receptor redirected T cells and methods of their useFORMAN STEPHEN·Filed 2013·Granted May 23, 2017·30 cites·18 claims
- 0984US10660916B2CD123-specific chimeric antigen receptor redirected T cells and methods of their useHOPE CITY·Filed 2017·Granted May 26, 2020·2 cites·18 claims
- 1082US11918606B2CD123-specific chimeric antigen receptor redirected t cells and methods of their useHOPE CITY·Filed 2020·Granted Mar 5, 2024·1 cites·20 claims
- 1182US11230577B2Chimeric antigen receptors containing a chlorotoxin domainHOPE CITY·Filed 2016·Granted Jan 25, 2022·3 cites·41 claims
- 1281US11701405B2Chimeric antigen receptors and methods for reducing toxicityHOPE CITY·Filed 2019·Granted Jul 18, 2023·1 cites·7 claims
- 1379US10590205B2Chimeric antigen receptor compositionsHOPE CITY·Filed 2017·Granted Mar 17, 2020·2 cites·17 claims
- 1479US2025333471A1Chimeric Antigen Receptors Targeting HER2HOPE CITY·Filed 2024·Application pending·0 cites
- 1576US11466097B2Chimeric antigen receptors targeted to PSCAHOPE CITY·Filed 2016·Granted Oct 11, 2022·1 cites·13 claims
- 1675US2024415963A1T cells for expression of chimeric antigen receptors and other receptorsHOPE CITY·Filed 2024·Application pending·0 cites
- 1774US12281151B2CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disordersHOPE CITY·Filed 2019·Granted Apr 22, 2025·1 cites·35 claims
- 1874US2025002850A1Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptorsHOPE CITY·Filed 2024·Application pending·0 cites
- 1971US2024148826A1Chimeric antigen receptors and methods for reducing toxicityHOPE CITY·Filed 2023·Application pending·0 cites
- 2069US12472233B2Administration of engineered T cells for treatment of cancers in the central nervous systemHOPE CITY·Filed 2020·Granted Nov 18, 2025·0 cites·16 claims
- 2168US2022265796A1Chimeric antigen receptors targeting her2HOPE CITY·Filed 2021·Application pending·0 cites
- 2268US2024058382A1Deterministic mechanoporation for cell engineeringUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 2365US12419954B2Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignanciesHOPE CITY·Filed 2021·Granted Sep 23, 2025·0 cites·20 claims
- 2463US2025368719A1Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disordersHOPE CITY·Filed 2025·Application pending·0 cites
- 2563US2020318069A1COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2HOPE CITY·Filed 2020·Application pending·0 cites
- 2663US2025263463A1Deterministic mechanoporation for cell engineeringUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 2761US2020277400A1Chimeric antigen receptor compositionsHOPE CITY·Filed 2020·Application pending·0 cites
- 2860US2022177528A1Chimeric antigen receptors containing a chlorotoxin domainHOPE CITY·Filed 2021·Application pending·0 cites
- 2959US12115189B2T cells for expression of chimeric antigen receptors and other receptorsHOPE CITY·Filed 2016·Granted Oct 15, 2024·0 cites·7 claims
- 3059US2024366662A1Car t cell therapy and ifn gammaHOPE CITY·Filed 2022·Application pending·0 cites
- 3157US2025320291A1Compositions and uses of cd19 targeted chimeric antigen receptor modified immune cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 3257US2023338531A1Compositions and uses of cd45 targeted chimeric antigen receptor modified t cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 3356US2022362300A1Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereofHOPE CITY·Filed 2020·Application pending·0 cites
- 3454US2022072043A1Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancerMUSTANG BIO INC·Filed 2021·Application pending·0 cites
- 3554US2022354852A1Targeting wnt signaling for improved glioma immunotherapyHOPE CITY·Filed 2022·Application pending·0 cites
- 3654US2017224733A1Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous SystemHOPE CITY·Filed 2017·Application pending·0 cites
- 3754US2016333108A1CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USEFORMAN STEPHEN J·Filed 2014·Application pending·0 cites
- 3854US2020040096A1CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USEHOPE CITY·Filed 2018·Application pending·0 cites
- 3953US2020095547A1Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptorsALIZADEH DARYA·Filed 2017·Application pending·0 cites
- 4053US2020289568A1Deterministic mechanoporation for cell engineeringUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 4152US2023364138A1Engineered t cells for expression of chimeric anitgen receptorsHOPE CITY·Filed 2021·Application pending·0 cites
- 4251US2023076643A1Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancersHOPE CITY·Filed 2020·Application pending·0 cites
- 4349US2023374085A1Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatmentHOPE CITY·Filed 2021·Application pending·0 cites
- 4447US2022145252A1Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptorsHOPE CITY·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christine E. Brown files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →